Scholarlink

Background <p>Inflammatory bowel disease is a significant health concern for both humans and large-scale farm animals. In the quest for effective alternatives to antibiotics, next-generation probiotics (NGPs) have emerged as a promising option. The genus <i>Blautia</i> presents a rich source of potential NGP strains. Here we successfully isolated <i>Blautia hominis</i> LYH1 strain from the intestines of healthy weaned piglets and characterized its biological traits. Its anti-inflammatory activity was then assessed using macrophages, while its protective effects against colitis and gut barrier damage were validated in a DSS-induced mouse colitis model.</p> Results <p><i>B. hominis</i> LYH1 displayed typical characteristics of an obligate anaerobe, including non-hemolytic and non-motile features, and a genome enriched with carbohydrate-active enzyme genes. It produced metabolites with antibiotic-like compounds, demonstrating antimicrobial activity against <i>Escherichia coli</i>. In vitro, <i>B. hominis</i> LYH1 effectively inhibited pathogen replication in macrophages, reducing cellular infections and alleviating inflammatory damage. In vivo, oral administration of <i>B. hominis</i> LYH1 or its metabolites significantly mitigated DSS-induced colitis in mice by suppressing pro-inflammatory cytokines, inhibiting T-lymphocyte activation, and enhancing short-chain fatty acid production.</p> Conclusions <p>Our findings underscore <i>B. hominis</i> LYH1’s potential as a NGP for maintaining gut health and combating intestinal inflammation. These findings offer valuable insights into the development of antibiotic alternatives and innovative strategies for preventing and treating enteritis in both agricultural and medical settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unlocking the power of swine gut bacteria: newly isolated Blautia strain and its metabolites inhibit the replication of Salmonella Typhimurium in macrophages and alleviate DSS-induced colitis in mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月23日

查看全文
  • Jiatong Wei,
  • Yang Liu,
  • Hua Li,
  • Ze Lu,
  • Yanjiao Liu,
  • Yifan Zhang,
  • Cong Lan,
  • Aimin Wu,
  • Jun He,
  • Jingyi Cai,
  • Gang Tian,
  • Daiwen Chen,
  • Bing Yu,
  • Zhiqing Huang,
  • Ping Zheng,
  • Xiangbing Mao,
  • Jie Yu,
  • Junqiu Luo,
  • Hui Yan,
  • Jiayong Tang,
  • Huifen Wang,
  • Quyuan Wang,
  • Yuheng Luo

摘要

Background

Inflammatory bowel disease is a significant health concern for both humans and large-scale farm animals. In the quest for effective alternatives to antibiotics, next-generation probiotics (NGPs) have emerged as a promising option. The genus Blautia presents a rich source of potential NGP strains. Here we successfully isolated Blautia hominis LYH1 strain from the intestines of healthy weaned piglets and characterized its biological traits. Its anti-inflammatory activity was then assessed using macrophages, while its protective effects against colitis and gut barrier damage were validated in a DSS-induced mouse colitis model.

Results

B. hominis LYH1 displayed typical characteristics of an obligate anaerobe, including non-hemolytic and non-motile features, and a genome enriched with carbohydrate-active enzyme genes. It produced metabolites with antibiotic-like compounds, demonstrating antimicrobial activity against Escherichia coli. In vitro, B. hominis LYH1 effectively inhibited pathogen replication in macrophages, reducing cellular infections and alleviating inflammatory damage. In vivo, oral administration of B. hominis LYH1 or its metabolites significantly mitigated DSS-induced colitis in mice by suppressing pro-inflammatory cytokines, inhibiting T-lymphocyte activation, and enhancing short-chain fatty acid production.

Conclusions

Our findings underscore B. hominis LYH1’s potential as a NGP for maintaining gut health and combating intestinal inflammation. These findings offer valuable insights into the development of antibiotic alternatives and innovative strategies for preventing and treating enteritis in both agricultural and medical settings.